Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC
Data files
Feb 25, 2025 version files 15.76 KB
-
30_Dataset.csv
2.69 KB
-
88_Dataset.csv
6.67 KB
-
README.md
6.40 KB
Abstract
This study evaluated the efficacy and safety of camrelizumab combined with platinum-based chemotherapy (taxanes [T] or fluorouracil agents [F] plus platinum [P] drugs) as the first-line treatment in advanced esophageal squamous cell carcinoma (ESCC), using immune repertoire sequencing (IRS) to explore treatment response mechanism. In this multi-center, prospective cohort study, 88 patients received camrelizumab plus TP or FP, achieving a 1-year progression-free survival of 56.8% and overall survival of 68.2%. The objective response rate (ORR) was 64.8%, with a disease control rate of 91.1%. While most treatment-related adverse events were mild, 12.5% of patients experienced grade ≥3 toxicities. IRS showed significant differences in T-cell receptor (TCR) b-chain and immunoglobulin heavy chain between patients with (ORR group) or without ORR (non-ORR group), particularly in the distribution and expression of some genes. Specifically, we found significant differences in the amino acid composition of complementarity determining region 3 (CDR3) polypeptide sequences in TCR and B-cell receptor (BCR) between the ORR and non-ORR groups. For TCR, we observed substantial oligoclonal enrichment and differences in the abundance of specific V and J genes. Similarly, for BCR, we detected differences in the clonotype abundance of CDR3 polypeptide segments and identified several differential V genes. Camrelizumab combined with platinum-based chemotherapy is effective and well-tolerated as the first-line treatment for ESCC, and IRS may reveal mechanisms influencing treatment response.
https://doi.org/10.5061/dryad.0cfxpnwcf
Description of the data and file structure
We collected clinical information from 88 patients and immune repertoire information from 30 patients.
We have provided R software analysis code for clinical data analysis.
Files and variables
File: 88_Dataset.xlsx
Description: We collected clinical information from 88 patients, including their tumor grade, ECOG performance status, cancer stage, tumor site, treatment group, treatment start and end dates, treatment duration (in days), number of immunotherapy cycles, number of combined immunotherapy and chemotherapy cycles, number of maintenance immunotherapy cycles, best efficacy evaluation, progression-free survival (PFS) status, progression time, PFS duration, overall survival (OS) status, OS time, OS duration, PD-L1 expression levels, timing of treatment-related adverse reactions, types of treatment-related adverse reactions, and the grading of these adverse reactions.
Variables
- Number of variables: 24
- Number of rows: 89
- Missing data value: NA
Here is a detailed explanation and definition of the clinical data variables collected from the 88 patients:
Tumor grade refers to the histological grade of the tumor, indicating its level of differentiation. ECOG performance status measures the patient's functional status on a scale from 0 (fully active) to 5 (dead). Cancer stage describes the extent of the disease based on the TNM staging system or other relevant criteria. Tumor site specifies the anatomical location of the tumor. Treatment group categorizes patients based on the type of treatment they received (1 represents the FP group, and 2 represents the TP group). Treatment start and end dates indicate the duration of treatment, while treatment duration (in days) calculates the total time between these dates.
Number of immunotherapy cycles refers to the total cycles of immunotherapy administered, while combined immunotherapy and chemotherapy cycles denote the number of cycles where both treatments were given. Maintenance immunotherapy cycles counts the cycles of immunotherapy for maintenance purposes after initial treatment. Best efficacy evaluation records the best response to treatment, such as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).
Progression-free survival (PFS) status indicates whether the patient experienced disease progression or remained progression-free, while progression time and PFS duration measure the time (in days) from the start of treatment to disease progression or the last follow-up. Overall survival (OS) status indicates if the patient is alive or deceased, and OS time and OS duration measure the time (in days) from treatment initiation to death or the last follow-up. PD-L1 expression levels provide information on the expression of the PD-L1 biomarker, which may predict response to immunotherapy.
Finally, the timing of treatment-related adverse reactions specifies when adverse events occurred during treatment, while the types of treatment-related adverse reactions describe the nature of these events (e.g., rash, fatigue). The grading of treatment-related adverse reactions classifies the severity of these events based on standardized criteria (e.g., Grades 1–5, with higher grades indicating more severe reactions).
File: 30_Dataset.xlsx
Description: We collected immune repertoire information from 30 patients, including their Sample ID, class, diversity metrics (Diversity, d50Index5, Shannon_norm5, Inverse_Simpson5, Diversity4, d50Index4, Shannon_norm4, Inverse_Simpson4), ECOG performance status, treatment group, treatment duration, progression status, progression-free survival (PFS) time, PFS status, survival status, total treatment time, time of death, and overall survival (OS) duration.
Variables
- Number of variables: 21
- Number of rows: 31
- Missing data value: NA
Here is a detailed explanation and definition of the immune repertoire data variables collected from the 30 patients:
The dataset includes Sample ID, which uniquely identifies each patient sample, and class, referring to the classification or subtype of the sample (Immune response, with 1 representing the non-ORR group and 2 representing the ORR group). The diversity metrics include several measures to quantify the diversity of immune repertoires: Diversity is a general measure of immune repertoire diversity, while d50Index5, Shannon_norm5, and Inverse_Simpson5 represent diversity metrics calculated based on the top 5 most abundant clones. Similarly, Diversity4, d50Index4, Shannon_norm4, and Inverse_Simpson4 are diversity metrics calculated for the top 4 most abundant clones. These metrics provide insights into the clonal distribution and richness of the immune repertoire.
ECOG performance status measures the patient’s functional status on a scale from 0 (fully active) to 5 (dead). Treatment group categorizes patients based on the type of treatment they received (e.g., immunotherapy, combination therapy). Treatment duration refers to the total time (in days) the patient underwent treatment. Progression status indicates whether the disease progressed during or after treatment, while progression-free survival (PFS) time measures the time (in days) from the start of treatment to disease progression or the last follow-up. PFS status records whether the patient remained progression-free or experienced disease progression.
Survival status indicates if the patient is alive or deceased at the time of follow-up. Total treatment time refers to the overall duration of treatment the patient received, and time of death specifies the date or time when the patient passed away (if applicable). Finally, overall survival (OS) duration measures the time (in days) from the start of treatment to death or the last follow-up, providing a key metric for evaluating patient outcomes.
Code/software
We have provided R software analysis code for clinical data analysis.